Meningococcal protein antigens and vaccines

Vaccine

Volumn 27, Issue SUPPL. 2, 2009, Pages

  Feavers, Ian M ^a   Pizza, Mariagrazia ^b  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Antigens; Meningococcus; Vaccines

Indexed keywords

ADHESIN; COMPLEMENT FACTOR H; LACTATE PERMEASE; LACTOFERRIN RECEPTOR; MENINGOCOCCUS VACCINE; NSPA PROTEIN; OUTER MEMBRANE PROTEIN; PORIN A; PORIN B; RLP2086 VACCINE; RMENB VACCINE; TRANSFERRIN BINDING PROTEIN A; TRANSFERRIN BINDING PROTEIN B; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTIBODY RESPONSE; ANTIGEN FUNCTION; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL SURVIVAL; BACTERIUM ADHERENCE; COMPLEMENT DEPENDENT CYTOTOXICITY; IRON TRANSPORT; LCTP GENE; MENINGOCOCCOSIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEOMICS; RAT; SERUM BACTERICIDAL ACTIVITY; VACCINE PRODUCTION;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS;

EID: 67349160449     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.001     Document Type: Article

References (151)

1. Stein D.M., Robbins J., Miller M.A., Lin F.Y., and Schneerson R. Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?. Vaccine 24 3 (2005) 221-228
2. Holst J, Martin D, Arnold R, Campa Huergo C, Oster P, O'Hallahan J, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine; this issue.
3. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338 8775 (1991) 1093-1096
4. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14 2 (1991) 195-207
5. Rouaud P., Perrocheau A., Taha M.K., Sesboue C., Forgues A.M., Parent dC.I., et al. Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005. Euro Surveill 11 7 (2006) 178-181
6. O'Hallahan J., Lennon D., Oster P., Lane R., Reid S., Mulholland K., et al. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 23 17-18 (2005) 2197-2201
7. Uli L., Castellanos-Serra L., Betancourt L., Dominguez F., Barbera R., Sotolongo F., et al. Outer membrane vesicles of the VA-MENGOC-BC(R) vaccine against serogroup B of Neisseria meningitidis: analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 6 11 (2006) 3389-3399
8. Vipond C., Suker J., Jones C., Tang C., Feavers I.M., and Wheeler J.X. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics 6 11 (2006) 3400-3413
9. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19 17-19 (2001) 2688-2691
10. Snape M.D., Dawson T., Morant A., John T., Ohene-Kena B., Borrow R., et al. Immunogenicty and reactogenicity of a novel serogroup B Neisseria meningitidis vaccine administered from 6 months of age. 16th international pathogenic Neisseria conference Rotterdam, The Netherlands (2008) p. 85
11. Maiden M.C.J., and Caugant D.A. The population biology of Neisseria meningitidis: implications for meningococcal disease, epidemiology and control. In: Frosch M., and Maiden M.C.J. (Eds). Handbook of meningococcal disease (2006), Wiley-VCH, Weinheim 17-35
12. Caugant D.A. Population genetics and molecular epidemiology of Neisseria meningitides. APMIS 106 5 (1998) 505-525
13. Parkhill J., Achtman M., James K.D., Bentley S.D., Churcher C., Klee S.R., et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 404 6777 (2000) 502-506
14. Tettelin H., Saunders N.J., Heidelberg J., Jeffries A.C., Nelson K.E., Eisen J.A., et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287 5459 (2000) 1809-1815
15. Feavers I.M. ABC of meningococcal diversity. Nature 404 6777 (2000) 451-452
16. Urwin R., Russell J.E., Thompson E.A., Holmes E.C., Feavers I.M., and Maiden M.C. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 72 10 (2004) 5955-5962
17. Bentley S.D., Vernikos G.S., Snyder L.A., Churcher C., Arrowsmith C., Chillingworth T., et al. Meningococcal genetic variation mechanisms viewed through comparative analysis of serogroup C strain FAM18. PLoS Genet 3 2 (2007) e23
18. Frasch C.E., Zollinger W.D., and Poolman J.T. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 7 4 (1985) 504-510
19. Feavers I.M., and Maiden M.C. A gonococcal porA pseudogene: implications for understanding the evolution and pathogenicity of Neisseria gonorrhoeae. Mol Microbiol 30 3 (1998) 647-656
20. van der Ley P., Heckels J.E., Virji M., Hoogerhout P., and Poolman J.T. Topology of outer membrane proteins in pathogenic Neisseria species. Infect Immun 59 9 (1991) 2963-2971
21. McGuinness B.T., Barlow A.K., Clarke I.N., Farley J.E., Anilionis A., Poolman J.T., et al. Deduced amino acid sequences of class 1 protein PorA from three strains of Neisseria meningitidis. J Exp Med 171 6 (1990) 1871-1882
22. Maiden M.C.J., Suker J., McKenna A.J., Bygraves J.A., and Feavers I.M. Comparison of the class 1 outer membrane proteins of eight serological reference strains of Neisseria meningitidis. Mol Microbiol 5 3 (1991) 727-736
23. Feavers I.M., Suker J., McKenna A.J., Heath A.B., and Maiden M.C.J. Molecular analysis of the serotyping antigens of Neisseria meningitidis. Infect Immun 60 9 (1992) 3620-3629
24. Jolley K.A., Gray S.J., Suker J., and Urwin R. Methods for typing meningococci. In: Frosch M., and Maiden M.C.J. (Eds). Handbook of meningococcal disease (2006), Wiley-VCH, Weinheim 37-52
25. Tommassen J., Vermeij P., Struyvé M., Benz R., and Poolman J.T. Isolation of Neisseria meningitidis mutants deficient in Class 1 (PorA) and Class 3 (PorB) outer membrane proteins. Infect Immun 58 5 (1990) 1355-1359
26. Minetti C.A., Blake M.S., and Remeta D.P. Characterization of the structure, function, and conformational stability of PorB class 3 protein from Neisseria meningitides. A porin with unusual physicochemical properties. J Biol Chem 273 39 (1998) 25329-25338
27. Minetti C., Song J., Colombini M., and Blake M.S. Meningococcal PorA Class 1 proteins exist in nature as a heterotrimeric porin with PorB proteins. 11th pathogenic Neisseria conference. Nice, France (1998)
28. Jansen C., Wiese A., Reubsaet L., Dekker N., de Cock H., Seydel U., et al. Biochemical and biophysical characterization of in vitro folded outer membrane porin PorA of Neisseria meningitidis. Biochim Biophys Acta 1464 2 (2000) 284-298
29. Marzoa J., Abel A., Sanchez S., Chan H., Feavers I., Criado M.T., et al. Analysis of outer membrane porin complexes of Neisseria meningitidis in wild-type and specific knock-out mutant strains. Proteomics 9 3 (2009) 648-656
30. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13 9 (1995) 821-829
31. Milagres L.G., Ramos S.R., Sacchi C.T., Melles C.E., Vieira V.S., Sato H., et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 62 10 (1994) 4419-4424
32. Rosenqvist E., Hoiby E.A., Wedege E., Bryn K., Kolberg J., Klem A., et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 63 12 (1995) 4642-4652
33. Wedege E., Hoiby E.A., Rosenqvist E., and Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun 66 7 (1998) 3223-3231
34. Martin S.L., Borrow R., van der L.P., Dawson M., Fox A.J., and Cartwright K.A. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 18 23 (2000) 2476-2481
35. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281 16 (1999) 1520-1527
36. Vermont C.L., van Dijken H.H., Kuipers A.J., van Limpt C.J., Keijzers W.C., van der E.A., et al. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect Immun 71 4 (2003) 1650-1655
37. van den Dobbelsteen G.P., van Dijken H.H., Pillai S., and van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 25 13 (2007) 2491-2496
38. Massari P., Ram S., Macleod H., and Wetzler L.M. The role of porins in neisserial pathogenesis and immunity. Trends Microbiol 11 2 (2003) 87-93
39. Michaelsen T.E., Aase A., Kolberg J., Wedege E., and Rosenqvist E. PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria. Vaccine 19 11-12 (2001) 1526-1533
40. Massari P., King C.A., Ho A.Y., and Wetzler L.M. Neisserial PorB is translocated to the mitochondria of HeLa cells infected with Neisseria meningitidis and protects cells from apoptosis. Cell Microbiol 5 2 (2003) 99-109
41. Urwin R., Holmes E.C., Fox A.J., Derrick J.P., and Maiden M.C. Phylogenetic evidence for frequent positive selection and recombination in the meningococcal surface antigen PorB. Mol Biol Evol 19 10 (2002) 1686-1694
42. Arigita C., Kersten G.F., Hazendonk T., Hennink W.E., Crommelin D.J., and Jiskoot W. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes. Vaccine 21 9-10 (2003) 950-960
43. Humphries H.E., Williams J.N., Blackstone R., Jolley K.A., Yuen H.M., Christodoulides M., et al. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis. Vaccine 24 1 (2006) 36-44
44. Wright J.C., Williams J.N., Christodoulides M., and Heckels J.E. Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect Immun 70 8 (2002) 4028-4034
45. Schryvers A.B., and Stojiljkovic I. Iron acquisition systems in the pathogenic Neisseria. Mol Microbiol 32 6 (1999) 1117-1123
46. Legrain M., Mazarin V., Irwin S.W., Bouchon B., Quentin-Millet M.-J., Jacobs E., et al. Cloning and characterization of Neisseria meningitidis genes encoding the transferrin-binding proteins Tbp1 and Tbp2. Gene 130 1 (1993) 73-80
47. Pintor M., Gomez J.A., Ferron L., Ferreiros C.M., and Criado M.T. Analysis of TbpA and TbpB functionality in defective mutants of Neisseria meningitidis. J Med Microbiol 47 9 (1998) 757-760
48. Stokes R.H., Oakhill J.S., Joannou C.L., Gorringe A.R., and Evans R.W. Meningococcal transferrin-binding proteins A and B show cooperation in their binding kinetics for human transferrin. Infect Immun 73 2 (2005) 944-952
49. Rokbi B., Mazarin V., Maitre Wilmotte G., and Quentin-Millet M.-J. Identification of two major families of transferrin receptors among Neisseria meningitidis strains based on antigenic and genomic features. FEMS Microbiol Lett 110 1 (1993) 51-57
50. Rokbi B., Renauld-Mongenie G., Mignon M., Danve B., Poncet D., Chabanel C., et al. Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: implication for the composition of a recombinant TbpB-based vaccine. Infect Immun 68 9 (2000) 4938-4947
51. Griffiths E., Stevenson P., and Ray R. Antigenic and molecular heterogeneity of the transferrin-binding protein of Neisseria meningitidis. FEMS Microbiol Lett 69 1-2 (1990) 31-36
52. Gorringe A.R., Borrow R., Fox A.J., and Robinson A. Human antibody response to meningococcal transferrin binding proteins: evidence for vaccine potential. Vaccine 13 13 (1995) 1207-1212
53. Danve B., Lissolo L., Mignon M., Dumas P., Colombani S., Schryvers A.B., et al. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine 11 12 (1993) 1214-1220
54. Ala'Aldeen D.A., and Borriello S.P. The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. Vaccine 14 1 (1996) 49-53
55. West D., Reddin K., Matheson M., Heath R., Funnell S., Hudson M., et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun 69 3 (2001) 1561-1567
56. Danve B., Lissolo L., Guinet F., Boutry E., Speck D., Cadoz M., et al. Safety and immunogenicity of a Neisseria meningitidis group B transferrin binding protein vaccine in adult. In: Nassif X., Quentin-Millet M.J., Taha M.K., et al. (Eds). 11th international pathogenic Neisseria conference. Paris, EDK (1998) 53
57. Halperin S.A., Langley J.M., Smith B., Wunderli P., Kaufman L., Kimura A., et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 25 3 (2007) 450-457
58. Richmond P., Marshall H., Nissen M.D., Lambert S., Jones T., Gruber W., et al. A randomized, observer-blinded, active control, phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescents aged 8 to 14 years. 16th international pathogenic Neisseria conference. Rotterdam, The Netherlands (2008) 270
59. Marshall H., Nissen M.D., Richmond P., Lambert S., Robertson D.M., Jones T., et al. A randomized, placebo-controlled, double-blind, phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine in healthy adults. 16th international pathogenic Neisseria conference. Rotterdam, The Netherlands (2008) 271
60. Miller E., Pollard A.J., Borrow R., Findlow J., Dawson T., Morant A., et al. Safety and immunogenicity of Novartis meningoccocal serogroup B vaccine (MenB vaccine) after three doses administered in infancy. 26th annual meeting of the european society for paediatric infectious diseases (ESPID). Graz, Austria (2008)
61. Pettersson A., van der L.P., Poolman J.T., and Tommassen J. Molecular characterization of the 98-kilodalton iron-regulated outer membrane protein of Neisseria meningitidis. Infect Immun 61 11 (1993) 4724-4733
62. Pettersson A., Prinz T., Umar A., van der B.J., and Tommassen J. Molecular characterization of LbpB, the second lactoferrin-binding protein of Neisseria meningitidis. Mol Microbiol 27 3 (1998) 599-610
63. Pettersson A., Kortekaas J., Weynants V.E., Voet P., Poolman J.T., Bos M.P., et al. Vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB. Vaccine 24 17 (2006) 3545-3557
64. Carson S.D., Klebba P.E., Newton S.M., and Sparling P.F. Ferric enterobactin binding and utilization by Neisseria gonorrhoeae. J Bacteriol 181 9 (1999) 2895-2901
65. Pettersson A., Maas A., van Wassenaar D., van der L.P., and Tommassen J. Molecular characterization of FrpB, the 70-kilodalton iron-regulated outer membrane protein of Neisseria meningitidis. Infect Immun 63 10 (1995) 4181-4184
66. Pettersson A., Kuipers B., Pelzer M., Verhagen E., Tiesjema R.H., Tommassen J., et al. Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific. Infect Immun 58 9 (1990) 3036-3041
67. van der Ley P., van der Biezen J., Sutmuller R., Hoogerhout P., and Poolman J.T. Sequence variability of FrpB, a major iron-regulated outer-membrane protein in the pathogenic neisseriae. Microbiology 142 11 (1996) 3269-3274
68. Thompson E.A., Feavers I.M., and Maiden M.C. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 149 7 (2003) 1849-1858
69. Stojiljkovic I., Larson J., Hwa V., Anic S., and So M. HmbR outer membrane receptors of pathogenic Neisseria spp.: iron-regulated, hemoglobin-binding proteins with a high level of primary structure conservation. J Bacteriol 178 15 (1996) 4670-4678
70. Stojiljkovic I., Hwa V., de Saint M.L., O'Gaora P., Nassif X., Heffron F., et al. The Neisseria meningitidis haemoglobin receptor: its role in iron utilization and virulence. Mol Microbiol 15 3 (1995) 531-541
71. Harrison OB, Evans NJ, Blair JM, Grimes HS, Tinsley CR, Nassif X, et al. Epidemiological evidence for the role of the haemoglobin receptor, HmbR, in meningococcal virulence. J Infect Dis; in press.
72. Lewis L.A., Gray E., Wang Y.P., Roe B.A., and Dyer D.W. Molecular characterization of hpuAB, the haemoglobin-haptoglobin utilization operon of Neisseria meningitidis. Mol Microbiol 23 4 (1997) 737-749
73. Sun Y., Li Y., Exley R.M., Winterbotham M., Ison C., Smith H., et al. Identification of novel antigens that protect against systemic meningococcal infection. Vaccine 23 32 (2005) 4136-4141
74. Bourdoulous S., and Nassif X. Mechanisms of attachment and invasion. In: Frosch M., and Maiden M.C.J. (Eds). Handbook of meningococcal disease (2006), Wiley-VCH, Weinheim 257-272
75. Scarselli M., Serruto D., Montanari P., Capecchi B., Adu-Bobie J., Veggi D., et al. Neisseria meningitidis NhhA is a multifunctional trimeric autotransporter adhesin. Mol Microbiol 61 3 (2006) 631-644
76. Peak I.R., Srikhanta Y., Dieckelmann M., Moxon E.R., and Jennings M.P. Identification and characterisation of a novel conserved outer membrane protein from Neisseria meningitidis. FEMS Immunol Med Microbiol 28 4 (2000) 329-334
77. Sjolinder H., Eriksson J., Maudsdotter L., Aro H., and Jonsson A.B. Meningococcal outer membrane protein NhhA is essential for colonization and disease by preventing phagocytosis and complement attack. Infect Immun 76 11 (2008) 5412-5420
78. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287 5459 (2000) 1816-1820
79. van Ulsen P., van Alphen L., Hopman C.T., van der Ende A., and Tommassen J. In vivo expression of Neisseria meningitidis proteins homologous to the Haemophilus influenzae Hap and Hia autotransporters. FEMS Immunol Med Microbiol 32 1 (2001) 53-64
80. Litt D.J., Savino S., Beddek A., Comanducci M., Sandiford C., Stevens J., et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis 190 8 (2004) 1488-1497
81. Hadi H.A., Wooldridge K.G., Robinson K., and a'Aldeen D.A. Identification and characterization of App: an immunogenic autotransporter protein of Neisseria meningitidis. Mol Microbiol 41 3 (2001) 611-623
82. St Geme J.W., de la Morena M.L., and Falkow S. A Haemophilus influenzae IgA protease-like protein promotes intimate interaction with human epithelial cells. Mol Microbiol 14 (1994) 217-233
83. Serruto D., Adu-Bobie J., Scarselli M., Veggi D., Pizza M., Rappuoli R., et al. Neisseria meningitidis App, a new adhesin with autocatalytic serine protease activity. Mol Microbiol 48 2 (2003) 323-334
84. Giuliani M.M., Adu-Bobie J., Comanducci M., Aricò B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103 29 (2006) 10834-10839
85. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Aricò B., Capecchi B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 195 11 (2002) 1445-1454
86. Desvaux M., Parham N.J., and Henderson I.R. The autotransporter secretion system. Res Microbiol 155 2 (2004) 53-60
87. Hoiczyk E., Roggenkamp A., Reichenbecher M., Lupas A., and Heesemann J. Structure and sequence analysis of Yersinia YadA and Moraxella UspAs reveal a novel class of adhesions. EMBO J 19 22 (2000) 5989-5999
88. Capecchi B., Adu-Bobie J., Di Marcello F., Ciucchi L., Masignani V., Taddei A., et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 55 3 (2005) 687-698
89. Martin P., van de Ven T., Mouchel N., Jeffries A.C., Hood D.W., and Moxon E.R. Experimentally revised repertoire of putative contingency loci in Neisseria meningitidis strain MC58: evidence for a novel mechanism of phase variation. Mol Microbiol 50 1 (2003) 245-257
90. Martin P., Makepeace K., Hill S.A., Hood D.W., and Moxon E.R. Microsatellite instability regulates transcription factor binding and gene expression. Proc Natl Acad Sci USA 102 10 (2005) 3800-3804
91. Comanducci M., Bambini S., Caugant D.A., Mora M., Brunelli B., Capecchi B., et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 72 7 (2004) 4217-4223
92. Fukasawa L.O., Gorla M.C., Lemos A.P., Schenkman R.P., Brandileone M.C., Fox J.W., et al. Immune response to native NadA from Neisseria meningitidis and its expression in clinical isolates in Brazil. J Med Microbiol 52 2 (2003) 121-125
93. Norheim G., Aseffa A., Yassin M.A., Mengistu G., Kassu A., Fikremariam D., et al. Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci. Clin Vaccine Immunol 15 5 (2008) 863-871
94. Mazzon C., Baldani-Guerra B., Cecchini P., Kasic T., Viola A., de BernardM, et al. IFN-γ and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A. J Immunol 179 6 (2007) 3904-3916
95. Franzoso S., Mazzon C., Sztukowska M., Cecchini P., Kasic T., Capecchi B., et al. Human monocytes/macrophages are a target of Neisseria meningitidis Adhesin A (NadA). J Leukoc Biol 83 5 (2008) 1100-1110
96. Sarkari J., Pandit N., Moxon E.R., and Achtman M. Variable expression of the Opc outer membrane protein in Neisseria meningitidis is caused by size variation of a promoter containing poly-cytidine. Mol Microbiol 13 2 (1994) 207-217
97. Seiler A., Reinhardt R., Sarkari J., Caugant D.A., and Achtman M. Allelic polymorphism and site-specific recombination in the opc locus of Neisseria meningitidis. Mol Microbiol 19 4 (1996) 841-856
98. Zhu P., Morelli G., and Achtman M. The opcA and (psi)opcB regions in Neisseria: genes, pseudogenes, deletions, insertion elements and DNA islands. Mol Microbiol 33 3 (1999) 635-650
99. Virji M., Makepeace K., Ferguson D.J., Achtman M., and Moxon E.R. Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. Mol Microbiol 10 3 (1993) 499-510
100. Virji M., Makepeace K., and Moxon E.R. Distinct mechanisms of interactions of Opc-expressing meningococci at apical and basolateral surfaces of human endothelial cells: the role of integrins in apical interactions. Mol Microbiol 14 1 (1994) 173-184
101. Carbonnelle E, Morand P, Bourdoulous S, Nassif X, Hill DJ, Griffiths NJ, et al., Meningococcal interactions with the host, Vaccine 2009; this issue.
102. Cunha C.S., Griffiths N.J., Murillo I., and Virji M. Neisseria meningitidis Opc invasin binds to the cytoskeletal protein alpha-actinin. Cell Microbiol 11 3 (2008) 389-485
103. Merker P., Tommassen J., Kusecek B., Virji M., Sesardic D., and Achtman M. Two-dimensional structure of the Opc invasin from Neisseria meningitidis. Mol Microbiol 23 2 (1997) 281-293
104. Jolley K.A., Appleby L., Wright J.C., Christodoulides M., and Heckels J.E. Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci. Infect Immun 69 6 (2001) 3809-3816
105. Virji M., Makepeace K., Ferguson D.J., and Watt S.M. Carcinoembryonic antigens (CD66) on epithelial cells and neutrophils are receptors for Opa proteins of pathogenic neisseriae. Mol Microbiol 22 5 (1996) 941-950
106. Virji M., Evans D., Hadfield A., Grunert F., Teixeira A.M., and Watt S.M. Critical determinants of host receptor targeting by Neisseria meningitidis and Neisseria gonorrhoeae: identification of Opa adhesiotopes on the N-domain of CD66 molecules. Mol Microbiol 34 3 (1999) 538-551
107. Virji M., Watt S.M., Barker S., Makepeace K., and Doyonnas R. The N-domain of the human CD66a adhesion molecule is a target for Opa proteins of Neisseria meningitidis and Neisseria gonorrhoeae. Mol Microbiol 22 5 (1996) 929-939
108. Malorny B., Morelli G., Kusecek B., Kolberg J., and Achtman M. Sequence diversity, predicted two-dimensional protein structure, and epitope mapping of neisserial Opa proteins. J Bacteriol 180 5 (1998) 1323-1330
109. de Jonge M.I., Bos M.P., Hamstra H.J., Jiskoot W., van Ulsen P., Tommassen J., et al. Conformational analysis of opacity proteins from Neisseria meningitidis. Eur J Biochem 269 21 (2002) 5215-5223
110. Aho E.L., Dempsey J.A., Hobbs M.M., Klapper D.G., and Cannon J.G. Characterization of the opa (class 5) gene family of Neisseria meningitidis. Mol Microbiol 5 6 (1991) 1429-1437
111. Stern A., and Meyer T.F. Common mechanism controlling phase and antigenic variation in pathogenic neisseriae. Mol Microbiol 1 1 (1987) 5-12
112. Callaghan M.J., Jolley K.A., and Maiden M.C. Opacity-associated adhesin repertoire in hyperinvasive Neisseria meningitidis. Infect Immun 74 9 (2006) 5085-5094
113. Callaghan M.J., Buckee C., McCarthy N.D., Ibarz Pavon A.B., Jolley K.A., Faust S., et al. Opa protein repertoires of disease-causing and carried meningococci. J Clin Microbiol 46 9 (2008) 3033-3041
114. Poolman J.T., Hopman C.T.P., and Zanen H.C. Immunogenicity of meningococcal antigens as detected in patient sera. Infect Immun 40 1 (1983) 398-406
115. Mandrell R.E., and Zollinger W.D. Human immune response to meningococcal outer membrane epitopes after natural infection or vaccination. Infect Immun 57 7 (1989) 1590-1598
116. Wedege E., and Froholm L.O. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun 51 2 (1986) 571-578
117. Wiertz E.J., Delvig A., Donders E.M., Brugghe H.F., van Unen L.M., Timmermans H.A., et al. T-cell responses to outer membrane proteins of Neisseria meningitidis: comparative study of the Opa, Opc, and PorA proteins. Infect Immun 64 1 (1996) 298-304
118. Tonjum T., Caugant D.A., Dunham S.A., and Koomey M. Structure and function of repetitive sequence elements associated with a highly polymorphic domain of the Neisseria meningitidis PilQ protein. Mol Microbiol 29 1 (1998) 111-124
119. Collins R.F., Frye S.A., Kitmitto A., Ford R.C., Tonjum T., and Derrick J.P. Structure of the Neisseria meningitidis outer membrane PilQ secretin complex at 12 A resolution. J Biol Chem 279 38 (2004) 39750-39756
120. Collins R.F., Frye S.A., Balasingham S., Ford R.C., Tonjum T., and Derrick J.P. Interaction with type IV pili induces structural changes in the bacterial outer membrane secretin PilQ. J Biol Chem 280 19 (2005) 18923-18930
121. Halliwell D., Frye S.A., Taylor S., Flockhart A., Finney M., Reddin K., et al. Immunisation with the meningococcal PilQ complex is protective in a mouse model of meningococcal disease and elicits bactericidal and opsonic antibodies. 14th international pathogenic Neisseria conference. Milwaukee, Wisconsin, USA, September 5-10 (2004) 161
122. Poolman J.T., Denoël P., Feron C., Goraj K., and Weynants V. Outer membrane vesicle-based meningococcal vaccines. In: Frosch M., and Maiden M. (Eds). Handbook of meningococcal disease (2006), Wiley-VCH, Weinheim 371-390
123. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72 4 (2004) 2088-2100
124. Cantini F., Veggi D., Dragonetti S., Savino S., Scarselli M., Romagnoli G., et al. Solution structure of the factor H binding protein, a survival factor and protective antigen of Neisseria meningitidis. J Biol Chem 284 14 (2009) 9022-9026
125. Schneider M.C., Prosser B.E., Caesar J.J., Kugelberg E., Li S., Zhang Q., et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458 7240 (2009) 890-893
126. Mascioni A., Bentley B.E., Camarda R., Dilts D.A., Fink P., Gusarova V., et al. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J Biol Chem 284 13 (2008) 8738-8746
127. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Aricò B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197 6 (2003) 789-799
128. Cantini F., Savino S., Scarselli M., Masignani V., Pizza M., Romagnoli G., et al. Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis. J Biol Chem 281 11 (2006) 7220-7227
129. Pillai S., Howell A., Alexander K., Bentley B.E., Jiang H.Q., Ambrose K., et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 23 17-18 (2005) 2206-2209
130. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177 1 (2006) 501-510
131. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.H., Sim R.B., et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 176 12 (2006) 7566-7575
132. Seib K.L., Serruto D., Oriente F., Delany I., Adu-Bobie J., Veggi D., et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 77 1 (2009) 292-299
133. Koeberling O., Welsch J.A., and Granoff D.M. Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870. Vaccine 25 10 (2007) 1912-1920
134. Martin D., Cadieux N., Hamel J., and Brodeur B.R. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 185 7 (1997) 1173-1183
135. Moe G.R., Tan S., and Granoff D.M. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 67 11 (1999) 5664-5675
136. Moe G.R., Zuno-Mitchell P., Lee S.S., Lucas A.H., and Granoff D.M. Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect Immun 69 6 (2001) 3762-3771
137. Vandeputte-Rutten L., Bos M.P., Tommassen J., and Gros P. Crystal structure of Neisserial surface protein A (NspA), a conserved outer membrane protein with vaccine potential. J Biol Chem 278 27 (2003) 24825-24830
138. Welsch J.A., Moe G.R., Rossi R., Adu-Bobie J., Rappuoli R., and Granoff D.M. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 188 11 (2003) 1730-1740
139. Faith N.G., Kathariou S., Neudeck B.L., Luchansky J.B., and Czuprynski C.J. A P60 mutant of Listeria monocytogenes is impaired in its ability to cause infection in intragastrically inoculated mice. Microb Pathog 42 5-6 (2007) 237-241
140. Sardinas G., Yero D., Climent Y., Caballero E., Cobas K., and Niebla O. Neisseria meningitidis antigen NMB0088: sequence variability, protein topology and vaccine potential. J Med Microbiol 58 2 (2009) 196-208
141. Delgado M., Yero D., Niebla O., González S., Climent Y., Pérez Y., et al. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate. Vaccine 25 50 (2007) 8420-8431
142. Jennings G.T., Savino S., Marchetti E., Arico B., Kast T., Baldi L., et al. GNA33 from Neisseria meningitidis serogroup B encodes a membrane-bound lytic transglycosylase (MltA). Eur J Biochem 269 15 (2002) 3722-3731
143. Adu-Bobie J., Lupetti P., Brunelli B., Granoff D., Norais N., Ferrari G., et al. GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence. Infect Immun 72 4 (2004) 1914-1919
144. Granoff D.M., Moe G.R., Giuliani M.M., Adu-Bobie J., Santini L., Brunelli B., et al. A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J Immunol 167 11 (2001) 6487-6496
145. Manning D.S., Reschke D.K., and Judd R.C. Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis are similar to Haemophilus influenzae D-15-Ag and Pasteurella multocida Oma87. Microb Pathog 25 1 (1998) 11-21
146. Gentle I., Gabriel K., Beech P., Waller R., and Lithgow T. The Omp85 family of proteins is essential for outer membrane biogenesis in mitochondria and bacteria. J Cell Biol 164 1 (2004) 19-24
147. Voulhoux R., Bos M.P., Geurtsen J., Mols M., and Tommassen J. Role of a highly conserved bacterial protein in outer membrane protein assembly. Science 299 5604 (2003) 262-265
148. Weynants V.E., Feron C.M., Goraj K.K., Bos M.P., Denoel P.A., Verlant V.G., et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun 75 11 (2007) 5434-5442
149. Sun Y.H., Bakshi S., Chalmers R., and Tang C.M. Functional genomics of Neisseria meningitidis pathogenesis. Nat Med 6 11 (2000) 1269-1273
150. Exley R.M., Goodwin L., Mowe E., Shaw J., Smith H., Read R.C., et al. Neisseria meningitidis lactate permease is required for nasopharyngeal colonization. Infect Immun 73 9 (2005) 5762-5766
151. Exley R.M., Wu H., Shaw J., Schneider M.C., Smith H., Jerse A.E., et al. Lactate acquisition promotes successful colonization of the murine genital tract by Neisseria gonorrhoeae. Infect Immun 75 3 (2007) 1318-1324